Cookies

Like most websites The Ophthalmologist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subspecialties Basic & Translational Research, Retina

Early Promise

Scientists from the Oklahoma Medical Research Foundation (OMRF) in Oklahoma City, have been studying the development of blood vessels, including one set that regresses and disappears in murine eyes after birth. The researchers discovered that down-regulation of a specific class of proteins called ETS transcription factors was responsible for this natural blood vessel loss in the eye. A compound called YK-4- 279 acts as an inhibitor of these ETS transcription factors and appeared to be particularly effective in low-flow vessels. The researchers decided to test the effectiveness of YK-4-279 in an oxygen-induced retinopathy mouse model that mimics human disease (including diabetic retinopathy and retinopathy of prematurity) and found: i) YK-4-279 reduced the abnormal neovascular tufts associated with the model and ii) the compound did not appear to affect healthy retinal vessels. Together, these discoveries point to the therapeutic potential of ETS transcription factor inhibitors (1).

Read the full article now

Log in or register to read this article in full and gain access to The Ophthalmologist’s entire content archive. It’s FREE!

Login

Or register now - it’s free!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

When you click “Register” we will email you a link, which you must click to verify the email address above and activate your account. If you do not receive this email, please contact us at [email protected].

About the Author

Aleksandra Jones

Editor of The Ophthalmologist

Having edited several technical publications over the last decade, I crossed paths with quite a few of Texere's current team members, and I only ever heard them sing the company's praises. When an opportunity arose to join Texere, I jumped at the chance! With a background in literature, I love the company's ethos of producing genuinely engaging content, and the fact that it is so well received by our readers makes it even more rewarding.

Newsletter

Send me the latest from The Ophthalmologist.

Sign up now

Most Popular

Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

Register